Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the Phase IIb RELIEVE UCCD trial of duvakitug.

And thank you all for taking the time to talk about this important program for Teva, our Duvakitug program. If I can have the next slide. Before we get started, I know that Duvakitug is the star ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

In ulcerative colitis, duvakitug led to clinical remission in ... Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...